ASCO in ActionASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.

To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.

Tune in to ASCO's new ASCO in Action podcast series, providing analysis and commentary on cancer policy and practice issues, available through iTunes or Google Play.

May 7, 2019

Today, the American Society of Clinical Oncology (ASCO) and the American Cancer Society Cancer Action Network (ACS CAN) hosted a joint reception on Capitol Hill for Members of Congress to underscore the two organizations’ shared policy priorities to improve research and cancer care delivery for patients and cancer survivors.

May 6, 2019

Early registration is now open for the ASCO Research Community Forum (RCF) 2019 Annual Meeting. The ASCO RCF Annual Meeting brings together physician investigators and research staff from across the country for two days of learning and collaboration. The meeting offers colleagues from a variety of types of research programs a unique platform to collaborate and develop solutions to common challenges with conducting oncology clinical trials.

May 5, 2019

Hospital Universitario Central De Asturias - Medical Oncology Service has become the fifth practice in Spain to receive Quality Oncology Practice Initiative (QOPI®) certification through QOPI Certification Program, LLC, and the eleventh practice internationally to receive this accreditation.

May 3, 2019

On May 3, 2019, the Food and Drug Administration approved ado-trastuzumab emtansine (KADCYLA®, Genentech, Inc.) for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.

May 2, 2019

On May 2, 2019, the Food and Drug Administration approved ivosidenib (TIBSOVO®, Agios Pharmaceuticals, Inc.) for newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy.

April 30, 2019

In an effort to understand how oncology providers are assessing older adults with cancer, ASCO is conducting a 5-minute survey among oncology providers about if, when, and how they obtain and interpret geriatric assessment findings and incorporate the findings into the cancer treatment decision-making process.

April 26, 2019

Mathematics, modeling, and simulation to study cancer are topics covered in a new special series in JCO Clinical Cancer Informatics (JCO CCI)

April 25, 2019

ASCO commends the 24 practices that took their standard of care to the next level and achieved Quality Oncology Practice Initiative (QOPI®) Certification in the first quarter of this year.

April 23, 2019

As part of ASCO’s State of Cancer Care in America™ initiative, the Journal of Oncology Practice published an infographic about opioids and cancer pain, which highlights the specific needs of patients with cancer and some of the hurdles they face in trying to access prescribed opioids to manage cancer-related pain.

April 22, 2019

Earlier this month, ASCO’s Quality Training Program held its first sessions in Romania and Greece, with a local practice in each location hosting the program’s one-day workshop.

April 19, 2019

On April 19, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA®, Merck & Co. Inc.) plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

April 12, 2019

ASCO is seeking to team with an oncology practice group in Brazil to host a new workshop that would provide an overview of the Society’s Quality Oncology Practice Initiative (QOPI®) and QOPI® Certification Program. Mission Endowment funding from Conquer Cancer, The ASCO Foundation, would cover the majority of the expenses for the course.

April 12, 2019

The Food and Drug Administration granted accelerated approval to erdafitinib (BALVERSA, Janssen Pharmaceutical Companies) for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
 

April 12, 2019

ASCO has submitted written testimony to the Texas House Committee on Insurance supporting legislation that requires health benefit plans to provide coverage for fertility preservation services to patients who will receive a medically necessary treatment such as chemotherapy or radiation. 

April 11, 2019

ASCO submitted testimony to the U.S. House and Senate Appropriations Committees urging them to increase funding for the National Institutes of Health, National Cancer Institute, and Food and Drug Administration.

Pages